ADC Therapeutics targets $600M-$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts
Source: SeekingAlpha
2025-08-12 11:29:24 ET
More on ADC Therapeutics
- ADC Therapeutics SA 2025 Q2 - Results - Earnings Call Presentation
- ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript
- ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript
- ADC reports data from lymphoma trial, streamlines operations
- ADC Therapeutics announces $100M private financing
Read the full article on Seeking Alpha
For further details see:
ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts
ADC Therapeutics SA
NASDAQ: ADCT
ADCT Trading
-5.62% G/L:
$4.20 Last:
295,591 Volume:
$4.36 Open:
ADCT Latest News
March 10, 2026 07:30:00 am
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADCT Stock Data
$486,217,661
104,923,913
12.45%
40
N/A
Biotechnology & Life Sciences
Healthcare
CH
Epalinges
